OVERVIEW
This free activity, entitled "Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease," consists of an activity overview, presentation, panel Q&A, a learning assessment, and an evaluation form. The content of this virtual lecture is derived from a webcast that took place on March 25, 2010.

MEDIA: Virtual Lecture or Podcast
INTERNET RELEASE DATE: April 21, 2010
(Continuing education credit is no longer available for this activity.)

Estimated time to complete this activity: 1 hour, 15 minutes

TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, and registered nurses who specialize in the care of patients with prostate cancer.

STATEMENT OF NEED
Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in nearly all prostate cancer patients who are treated with androgen-deprivation therapy. Recent research has suggested that androgen receptor expression is important for regulation of tumor growth, reflecting a shift away from the widely held belief that CRPC is androgen-independent.1 While researchers contemplate the implications of these new findings, healthcare professionals are faced with the challenge of tailoring therapy to individual patients. When choosing between second-line hormonal therapy and chemotherapy, physicians need to consider serum markers, patient age and pre-existing comorbidities, and toxic late effects of therapy that may affect outcomes and patient quality of life.2,3 Patients with aggressive disease may benefit from investigational strategies, but the current body of literature lacks consensus for directing such treatment decisions.3 As such, healthcare professionals who treat patients with CRPC would benefit from educational activities that outline optimal methods of defining, assessing, and treating this condition.

1 Mohler JL. Adv Exp Med Biol. 2008;617:223-234.
2 Hall WH, et al. Prostate Cancer Prostatic Dis. 2005;8:22-30.
3 Shepard DR, Raghavan D. Nat Rev Clin Oncol. 2010;7(1):13-21.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Outline clinical criteria for the classification of castrate-metastatic prostate cancer (CMPC)
• Describe therapeutic options for patients with progressive CMPC
• Summarize data for emerging therapies in CMPC
• Apply clinical evidence for best treatment strategies in CMPC to improve patient care

METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. During the period April 21, 2010, through April 21, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the learning assessment by recording the best answer to each question in the "Learning Assessment Answers" box on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with the learning assessment answers to Postgraduate Institute for Medicine. You may also complete the learning assessment online at www.cmeuniversity.com. Click on “Find Post-Test/Evaluation by Course” on the navigation menu, and search by Project ID 7250.

Participants must receive a score of at least 70% on the learning assessment and must complete and submit the evaluation form to successfully complete this activity. Participants who successfully complete the learning assessment and evaluation form via www.cmeuniversity.com will have a statement of credit made available immediately. Participants who successfully complete this activity and submit the learning assessment and evaluation form via fax or mail will be issued a statement of credit via US mail in 4 to 6 weeks.

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM). PIM is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
PIM designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
ACCREDITATION STATEMENT
Postgraduate Institute for Medicine (PIM) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION
PIM designates this educational activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. (University Activity Number – 0809-9999-10-090-H01-P)

If you have received credit for UAN 0809-9999-10-082-L01-P, you are not eligible for this activity.

ACTIVITY TYPE: Knowledge

NURSING CONTINUING EDUCATION
CREDIT DESIGNATION
This educational activity for 1.2 contact hours is provided by Postgraduate Institute for Medicine (PIM).

ACCREDITATION STATEMENT
PIM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CALIFORNIA BOARD OF REGISTERED NURSING
PIM is approved by the California Board of Registered Nursing, Provider Number 13485 for 1.5 contact hours.

FACULTY
Robert Dreicer, MD, MS, FACP
Chairman, Department of Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of continuing education (CE) activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

• Robert Dreicer, MD, MS, FACP, has affiliations with Ortho-McNeil, Endo Pharmaceuticals, Celgene Corporation, Astra-Zeneca (Consultant); Millennium Pharmaceuticals, Inc. (Research, Consulting); Eli Lilly and Company (Research); and sanofi-aventis (Honoraria).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Robert Michael Educational Institute LLC

• Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
• Laura Altobelli, MS, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine

• Jan Hixon, RN, BSN, MA, has no affiliations with commercial interests to disclose.
• Trace Hutchison, PharmD, has no affiliations with commercial interests to disclose.
• Julia Kirkwood, RN, BSN, has no affiliation with commercial interests to disclose.
• Jan Schultz, RN, MSN, CCMEP, has no affiliations with commercial interests to disclose.
  

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Robert Michael Educational Institute LLC (RMEI), sanofi-aventis, and Genentech do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, RMEI, sanofi-aventis, or Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

QUESTIONS & TECHNICAL ASSISTANCE
For questions regarding the content of this activity, contact the accredited provider for this continuing education activity: jjones@pimed.com. For technical assistance, contact jungsen@rmcom.net.

SYSTEM REQUIREMENTS
Hardware/Software requirements include:
• Windows XP, 2000, Vista, Windows 7   
  - Internet Explorer 6.0+
• Macintosh 9.2, OS X 10.1+
  - Safari 4+
• Additional Requirements
  - Macromedia Flash Player 10
  - Internal/external speakers
  - Broadband connection (DSL/cable) recommended

FOR MORE INFORMATION:

Additional educational activities offered by Robert Michael Educational Institute LLC can be found at www.RMEI.com or by calling toll-free to 866-770-RMEI.

PIM Privacy Policy        RMEI Privacy Statement